Clinical Report: Semaglutide Tested in Alcohol Use Disorder

Overview

A randomized clinical trial demonstrated that once-weekly semaglutide significantly reduced heavy drinking days among patients with alcohol use disorder and obesity compared to placebo over 26 weeks. The findings suggest potential for GLP-1 receptor agonists as a novel treatment option in this population.

Background

Alcohol use disorder (AUD) is a significant public health concern, particularly among individuals with obesity, as it complicates treatment and increases health risks. Current treatment options are limited, including behavioral therapies and medications with variable efficacy. There is a growing interest in exploring pharmacological alternatives. This study evaluates the efficacy of semaglutide, a GLP-1 receptor agonist, in reducing alcohol consumption in patients with AUD and obesity.

Data Highlights

Key Findings

• Semaglutide reduced heavy drinking days by 41 percentage points compared to 26 percentage points with placebo.
• Total alcohol consumption decreased by 1,550 g in the semaglutide group versus 1,026 g in the placebo group.
• Patients receiving semaglutide experienced greater reductions in alcohol cravings and improved scores on alcohol use assessments.
• Bodyweight decreased by 11.2 kg with semaglutide compared to 2.2 kg with placebo.
• Adverse events were primarily gastrointestinal, with nausea reported in 57% of semaglutide patients, which clinicians should consider when discussing treatment options.
• The number needed to treat for a two-level decrease in WHO risk drinking level was 4.3 with semaglutide, indicating a favorable treatment effect.

Clinical Implications

The findings indicate that semaglutide may be an effective adjunctive treatment for patients with alcohol use disorder and obesity, potentially enhancing outcomes when combined with cognitive behavioral therapy. Clinicians should consider the gastrointestinal side effects associated with semaglutide when discussing treatment options with patients, as the combination of therapy may influence overall effectiveness.

Conclusion

This study supports the potential role of GLP-1 receptor agonists like semaglutide in the management of alcohol use disorder, warranting further investigation and consideration in clinical practice, particularly regarding long-term effects and generalizability.

Related Resources & Content

1. National Institutes of Health (NIH), Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking, 2026 -- Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking
2. The New Gastroenterologist, Semaglutide Treatment Enhances Liver Histology in Patients with MASH, 2025 -- Semaglutide Treatment Enhances Liver Histology in Patients with MASH
3. conexiant, GLP-1 Drugs Examined in Psychiatric Outcomes -- GLP-1 Drugs Examined in Psychiatric Outcomes
4. Recommend Evidence-Based Treatment: Know the Options | National Institute on Alcohol Abuse and Alcoholism (NIAAA) -- Recommend Evidence-Based Treatment: Know the Options
5. conexiant — Dual Therapy Boosts Weight Loss in Trial 
6. Recommend Evidence-Based Treatment: Know the Options | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
7. Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking | National Institutes of Health (NIH)
8. The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis - PMC